Sarepta Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company is a recognized leader in precision genetic medicine, particularly for neuromuscular disorders such as Duchenne muscular dystrophy (DMD). Sarepta's commercial portfolio includes several approved treatments for DMD, notably EXONDYS 51, VYONDYS 53, AMONDYS 45, and its flagship gene therapy ELEVIDYS. The company operates in a single segment dedicated to discovering, developing, manufacturing, and delivering these transformative therapies to patients globally.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A comprehensive restructuring plan initiated in July 2025 to reduce operating expenses, align cost structures, and prioritize high-impact programs, particularly focusing on the siRNA platform.
Expected impact: Projected to deliver approximately $400 million in annual cost reductions, including $120 million from a 36% workforce reduction (approx. 500 employees) and $300 million in annual non-personnel savings, lowering average annual non-GAAP R&D and SG&A expenses to $800M-$900M.
Advancing a clinical-stage siRNA portfolio targeting neuromuscular diseases, highlighted by SRP-1001 for FSHD1 and SRP-1003 for DM1.
Expected impact: Establishes a potentially best-in-class chronic, scalable RNAi therapeutic engine to drive long-term growth beyond the core Duchenne portfolio.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Sarepta with exclusive global rights to multiple clinical and preclinical RNAi programs (including SRP-1001, SRP-1003, SRP-1002, and SRP-1004) leveraging Arrowhead's TRiM platform, marking a strategic pivot toward chronic, scalable RNAi medicines.
Terms: $500 million upfront payment, $325 million equity investment in Arrowhead common stock, $250 million in annual installments of $50 million over five years, up to $300 million in near-term enrollment milestones, and up to $10.3 billion in potential development and sales milestones.
Provides Roche with exclusive commercial rights to ELEVIDYS (delandistrogene moxeparvovec) outside the United States, combining Sarepta's gene therapy leadership with Roche's global commercial and regulatory reach.
Terms: $1.15 billion upfront payment and equity investment, up to $1.7 billion in regulatory and sales milestones, and tiered royalties on ex-U.S. net sales in the mid-teens, with global development expenses shared equally.
Leverages Dyno's AI-powered CapsidMap platform to design and discover next-generation AAV vectors with improved muscle-targeting capabilities, selectivity, and safety profiles for gene therapies.
Terms: Dyno eligible to receive over $40 million in upfront, option, and license payments during the research phase, plus additional milestone payments and royalties on worldwide net sales.